Kairos Pharma Announces Board & Executive Changes
Ticker: KAPA · Form: 8-K · Filed: Oct 15, 2025 · CIK: 1962011
| Field | Detail |
|---|---|
| Company | Kairos Pharma, LTD. (KAPA) |
| Form Type | 8-K |
| Filed Date | Oct 15, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0, $950,000, $1, $250,000, $225,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, executive-compensation, board-of-directors
TL;DR
Kairos Pharma shakes up board & exec pay - new era begins?
AI Summary
Kairos Pharma, LTD. announced on October 8, 2025, a change in its board of directors and executive compensation arrangements. The filing details the departure of certain officers and the election of new directors, alongside updates to compensatory arrangements for key personnel. The company is incorporated in Delaware and its principal executive offices are located in Los Angeles, CA.
Why It Matters
Changes in a company's board and executive compensation can signal shifts in strategy, operational focus, or financial health, impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in leadership and compensation can introduce uncertainty regarding future strategy and execution.
Key Numbers
- 001-42275 — SEC File Number (Identifies the company's filing with the SEC.)
- 46-2993314 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Kairos Pharma, LTD. (company) — Registrant
- Delaware (jurisdiction) — State of incorporation
- 2355 Westwood Blvd. , #139 Los Angeles CA 90064 (address) — Principal executive offices
- October 8, 2025 (date) — Earliest event reported
FAQ
What specific roles have seen departures or appointments?
The filing indicates changes related to 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers' and 'Compensatory Arrangements of Certain Officers', but specific names and roles are not detailed in this excerpt.
When was the earliest event reported in this filing?
The earliest event reported is dated October 8, 2025.
What is Kairos Pharma's principal business address?
The principal executive offices are located at 2355 Westwood Blvd., #139, Los Angeles, CA 90064.
What is the company's SIC code?
The Standard Industrial Classification code is 2834, which corresponds to Pharmaceutical Preparations.
What is the company's fiscal year end?
The company's fiscal year ends on December 31.
Filing Stats: 880 words · 4 min read · ~3 pages · Grade level 11.2 · Accepted 2025-10-15 16:10:43
Key Financial Figures
- $0 — ch registered Common Stock, par value $0.001, per share KAPA NYSE American
- $950,000 — y approved the grant of an aggregate of $950,000 restricted stock units ("RSUs") under t
- $1 — alculated based on a per share price of $1.31, which was the closing price of the
- $250,000 — rd, who received 190,840 RSUs valued at $250,000; Neil Bhomick, our Chief Scientific Off
- $225,000 — er, who received 171,756 RSUs valued at $225,000; Ramachandran Murali, our Vice Presiden
- $200,000 — nt, who received 152,672 RSUs valued at $200,000; and Doug Samuelson, our Chief Financia
- $25,000 — vi, each received19,084 RSUs, valued at $25,000. In addition to the RSU grants descri
- $87,500 — r 2024. Dr. Yu received a cash bonus of $87,500; Dr. Bhomick received a cash bonus of $
- $50,000 — 0; Dr. Bhomick received a cash bonus of $50,000; Dr. Murali received a cash bonus of $4
- $40,000 — 00; Dr. Murali received a cash bonus of $40,000; and Mr. Samuelson received a cash bonu
- $227,500 — approved for the executive officers was $227,500. Each RSU represents the right to rec
Filing Documents
- form8-k.htm (8-K) — 39KB
- ex10-1.htm (EX-10.1) — 41KB
- 0001493152-25-018145.txt ( ) — 250KB
- kapa-20251008.xsd (EX-101.SCH) — 3KB
- kapa-20251008_lab.xml (EX-101.LAB) — 33KB
- kapa-20251008_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description of Document 10.1 Form of Restricted Stock Unit Grant Agreement 104 Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL Document SIGNATURE Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: October 15, 2025 KAIROS PHARMA, LTD. By: /s/ John S. Yu John S. Yu Chief Executive Officer